Avon, Massachusetts-based Ranfac Corp. and Marshfield, Massachusetts-based Endocellutions, LLC have announced a new joint venture, Cervos Medical, a medical device company focused on surgical and orthobiologic devices.
Ranfac and Endocellutions Form Cervos Medical
1 min read Premium comments
Secondary#cervosmedical#endocellutions#ranfac
Cervos Medical will be the exclusive supplier of all Ranfac and Endocellutions co-developed products. This includes “bone marrow aspiration devices” based on the Marrow Cellution™ technology. Cervos Medical plans to “work closely with the distribution and provider community to promote, train and support” its products in the marketplace.
Cervos Medical will offer products across a range of specialties including extremities, orthopedics, trauma, sports medicine, ortho spine, neuro spine, pain management, intradiscal, plastic surgery, and oncology. According to the Cervos Medical website, its featured products include the following: CER-ORTHO, drill enabled bone marrow aspiration; CER-BN-116, drill enabled cancellous bone harvesting; CER-SUB-83N, drill enabled sub chondral access and delivery site preparation kit; and CF-S25X25, highly crosslinked carbohydrate synthetic graft material.
Both companies expressed excitement about the joint venture. Ranfac CEO Harlan Adler said, “I am extremely excited to announce the formation of Cervos Medical. We have partnered with the Endo team for over 5 years and believe this to be an important next step as we continue to bring next generation devices to the marketplace. The proven advantages of the Marrow Cellution™ technology with its elimination of the need for centrifugation, along with its demonstrated higher quality biologic is especially important with the focus on disease transmission and infection in the age of COVID.”
In addition to expressing his excitement about partnering with Ranfac, Endocellutions CEO Andrew McGillicuddy elaborated on Cervos Medical, commenting, “Cervos [Medical] will focus on ongoing customer education and peer-to-peer engagement to share best practices and work closely with the distribution community. We have put together a great team in a very dynamic space and I am very excited and proud to be a part of it.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.